Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Die Kardiologie
Erschienen in: Die Kardiologie 5/2018

03.09.2018 | Akutes Koronarsyndrom | CME

Management des akuten Koronarsyndroms

verfasst von: PD Dr. med. C. Liebetrau, A. Elsässer, H. Nef, H. Möllmann

Erschienen in: Die Kardiologie | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das akute Koronarsyndrom (ACS) ist häufig und prognostisch relevant. Insbesondere die kardialen Troponine sind neben dem 12-Kanal-EKG für die Risikostratifizierung und Diagnose wichtig. Mit der Verwendung der hochsensitiven Troponinbestimmung sind im klinischen Alltag eine schnelle Diagnosestellung und Behandlung von Patienten mit akutem Koronarsyndrom ohne ST-Streckenhebung (NSTE-ACS) möglich. Der Zeitpunkt der Koronarangiographie ist abhängig von der klinischen Situation und sollte bei Patienten mit STEMI ohne Verzögerung innerhalb von 120 min nach medizinischem Erstkontakt erfolgen. Bei NSTE-ACS-Patienten mit nachgewiesener Troponindynamik sollte die invasive Diagnostik innerhalb von 24 h, bei Hochrisikopatienten umgehend erfolgen. Unabhängig von der Revaskularisationsstrategie sollte eine duale antithrombozytäre Therapie mit Ticagrelor oder Prasugrel unter Berücksichtigung von Kontraindikationen für 12 Monate erfolgen. Clopidogrel ist nur noch bei Patienten mit einer Indikation zur oralen Antikoagulation oder bei Patienten mit stattgehabter zerebraler Blutung zu verwenden.
Literatur
1.
Ibánez B, James S, Agewall S et al (2018) 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 39:119–177 (The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC))CrossRefPubMed
2.
Roffi M, Patrono C, Collet JP et al (2016) 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 37:267–315 (The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC))CrossRefPubMed
3.
4.
Yeh RW, Sidney S, Chandra M et al (2010) Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 362:2155–2165CrossRefPubMed
5.
Keller T, Zeller T, Peetz D et al (2009) Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 361:868–877CrossRefPubMed
6.
Keller T, Zeller T, Ojeda F et al (2011) Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction. JAMA 306:2684–2693CrossRefPubMed
7.
Möllmann H, Liebetrau C, Nef HM et al (2011) The Swedish paradox: or is there really no gender difference in acute coronary syndromes? Eur Heart J 32:3070–3072CrossRefPubMed
8.
Thygesen K, Alpert JS, Jaffe AS et al (2012) Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Eur Heart J 33:2551–2567CrossRefPubMed
9.
Mozaffarian D, Benjamin EJ, Go AS et al (2016) Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation 133:e38–e360CrossRefPubMed
10.
Kim HW, Klem I, Shah DJ et al (2009) Unrecognized non-Q-wave myocardial infarction: prevalence and prognostic significance in patients with suspected coronary disease. PLoS Med 21:e1000057CrossRef
11.
12.
Terkelsen CJ, Sorensen JT, Maeng M et al (2010) System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. JAMA 304:763–771CrossRefPubMed
13.
Thygesen K, Mair J, Giannitsis E et al (2012) How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 33:2252–2257CrossRefPubMed
14.
Liebetrau C, Möllmann H, Nef H et al (2012) Release kinetics of cardiac biomarkers in patients undergoing transcoronary ablation of septal hypertophy. Clin Chem 58:1049–1054CrossRefPubMed
15.
Giannitsis E, Becker M, Kurz K et al (2010) High-sensitivity cardiac Troponin T for early prediction of evolving non-ST-segment elevation myocardial infarction in patients with suspected acute coronary syndrome and negative Troponin results on admission. Clin Chem 56:642–650CrossRefPubMed
16.
Weber M, Bazzino O, Navarro Estrada JL et al (2011) Improved diagnostic and prognostic performance of a new high-sensitive troponin T assay in patients with acute coronary syndrome. Am Heart J 162:81–88CrossRefPubMed
17.
Omland T, Pfeffer MA, Solomon SD et al (2013) Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. J Am Coll Cardiol 61:1240–1249CrossRefPubMed
18.
Liebetrau C, Weber M, Tzikas S et al (2015) Identification of acute myocardial infarction in patients with atrial fibrillation and chest pain with a contemporary sensitive troponin I assay. BMC Med 13:169CrossRefPubMedPubMedCentral
19.
Mueller M, Biener M, Vafaie M et al (2012) Absolute and relative kinetic changes of high-sensitivity cardiac troponin T in acute coronary syndrome and in patients with increased troponin in the absence of acute coronary syndrome. Clin Chem 58:209–218CrossRefPubMed
20.
Haaf P, Drexler B, Reichlin T et al (2012) High-sensitivity cardiac troponin in the distinction of acute myocardial infarction from acute cardiac noncoronary artery disease. Circulation 126:31–40CrossRefPubMed
21.
Neumann JT, Sörensen NA, Schwemer T et al (2016) Diagnosis of myocardial infarction using a high-sensitivity Troponin I 1‑hour algorithm. JAMA Cardiol 1:397–404CrossRefPubMed
22.
Reichlin T, Twerenbold R, Wildi K et al (2015) Prospective validation of a 1-hour algorithm to rule-out and rule-in acute myocardial infarction using a high-sensitivity cardiac troponin T assay. CMAJ 187:E243–52CrossRefPubMedPubMedCentral
23.
Zairis MN, Adamopoulou EN, Manousakis SJ et al (2007) The impact of hs C‑reactive protein and other inflammatory biomarkers on long-term cardiovascular mortality in patients with acute coronary syndromes. Atherosclerosis 194:397–402CrossRefPubMed
24.
Liebetrau C, Hoffmann J, Dörr O et al (2015) Release kinetics of inflammatory biomarkers in a clinical model of acute myocardial infarction. Circ Res 116:867–875CrossRefPubMed
25.
Liebetrau C, Nef H, Szardien S et al (2013) Release kinetics of copeptin in patients undergoing transcoronary ablation of septal hypertrophy. Clin Chem 59:566–569CrossRefPubMed
26.
Möckel M, Searle J, Hamm C et al (2015) Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study. Eur Heart J 36:369–376CrossRefPubMed
27.
Khan SQ, Dhillon OS, O’Brien RJ et al (2007) C‑terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 115:2103–2110CrossRefPubMed
28.
Hoffmann U, Bamberg F, Chae CU et al (2009) Coronary computed tomography angiography for early triage of patients with acute chest pain: the ROMICAT (Rule Out Myocardial Infarction using Computer Assisted Tomography) trial. J Am Coll Cardiol 53:1642–1650CrossRefPubMedPubMedCentral
29.
Dedic A, Lubbers MM, Schaap J et al (2016) Coronary CT angiography for suspected ACS in the era of high-sensitivity troponins: randomized multicenter study. J Am Coll Cardiol 67:16–26CrossRefPubMed
30.
Ferencik M, Liu T, Mayrhofer T et al (2015) hs-Troponin I followed by CT angiography improves acute coronary syndrome risk stratification accuracy and work-up in acute chest pain patients: results from ROMICAT II trial. Jacc Cardiovasc Imaging 8:1272–1281CrossRefPubMedPubMedCentral
31.
Liebetrau C, Gaede L, Dörr O et al (2015) High-sensitivity cardiac troponin T and copeptin assays to improve diagnostic accuracy of exercise stress test in patients with suspected coronary artery disease. Eur J Prev Cardiol 22:684–692CrossRefPubMed
32.
Stub D, Smith K, Bernard S et al (2015) Air versus oxygen in ST-segment-elevation myocardial infarction. Circulation 131:2143–2150CrossRefPubMed
33.
Chen ZM, Pan HC, Chen YP et al (2005) Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366:1622–1632CrossRefPubMed
34.
Montalescot G, Zeymer U, Silvain J et al (2011) Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet 378:693–703CrossRefPubMed
35.
Yusuf S, Mehta SR, Chrolavicius S et al (2006) Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354:1464–1476CrossRefPubMed
36.
Freimark D, Matetzky S, Leor J et al (2002) Timing of aspirin administration as a determinant of survival of patients with acute myocardial infarction treated with thrombolysis. Am J Cardiol 89:381–385CrossRefPubMed
37.
Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015CrossRefPubMed
38.
Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057CrossRefPubMed
39.
Montalescot G, Bolognese L, Dudek D et al (2013) Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 369:999–1010CrossRefPubMed
40.
Montalescot G, van’t Hof AW et al (2014) Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 371:1016–1027CrossRefPubMed
41.
Bonaca MP, Bhatt DL, Cohen M et al (2015) Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372:1791–1800CrossRefPubMed
42.
Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimský P, Tousek F, Tauth J, Spriggs D, McLaurin BT et al (2013) Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 368:1303–1313CrossRefPubMed
43.
Stone GW, Witzenbichler B, Guagliumi G et al (2011) Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3‑year results from a multicentre, randomised controlled trial. Lancet 377:2193–2204CrossRefPubMed
44.
TASTE Trial, Frobert O, Lagerqvist B, Olivecrona GK et al (2013) Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med 369:1587–1597CrossRef
45.
TOTAL Investigators, Jolly SS, Cairns JA, Yusuf S et al (2015) Randomized trial of primary PCI with or without routine manuel thrombectomy. N Engl J Med 372:1389–1398CrossRef
46.
Raber L, Kelbaek H, Ostojic M, Baumbach A, Heg D, Tuller D, von Birgelen C, Roffi M, Moschovitis A, Khattab AA, Wenaweser P, Bonvini R, Pedrazzini G, Kornowski R, Weber K, Trelle S, Luscher TF, Taniwaki M, Matter CM, Meier B, Juni P, Windecker S, COMFORTABLE AMI Trial Investigators (2012) Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA 308(8):777–787CrossRefPubMed
47.
Pi Y, Roe MT, Holmes ND et al (2017) Utilization, characteristics, an in-hospital outcomes of coronary artery bypass grafting in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Qual Outcomes 10:e3490 (Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry—get with the guidelines)CrossRefPubMed
48.
PRAMI Investigators, Wald DS, Morris JK, Wald NJ et al (2013) Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med 8:1190–1198
49.
Gershlick AH, Khan JN, Kelly DJ et al (2015) Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol 65:963–972CrossRefPubMedPubMedCentral
50.
DANAMI-3-PRIMULTI Investigators, Engstrom T, Kelbaek H, Helqvist S et al (2015) Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3-PRIMULTI): An open-label, randomized controlled trial. Lancet 386:665–671CrossRef
51.
Compare Acute Investigators, Smits P, Abdel-Wahab M, Neumann FJ et al (2017) Fractional flow reserve-guided multivessel angioplasty in myocardial infarction. N Engl J Med 376:1234–1244CrossRef
52.
Jensen LO, Thayssen P, Farkas DK et al (2012) Culprit only or multivessel percutaneous coronary interventions in patients with ST-segment elevation myocardial infarction and multivessel disease. EuroIntervention 8:456–464CrossRefPubMed
53.
CULPRIT-SHOCK Investigators, Thiele H, Akin I, Sandri M et al (2017) PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med 377:2419–2432CrossRef
54.
Yeh RW, Secemsky EA, Kereiakes DJ et al (2016) DAPT Study Investigators. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA 315:1735–1749CrossRefPubMedPubMedCentral
55.
Costa F, van Klaveren D, James S et al (2017) Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient dataset from clinical trials. Lancet 389:1025–1034CrossRefPubMed
56.
Eikelboom JW, Connolly SJ, Bosch J et al (2017) Rivaroxaban with or without Aspirin in stable cardiovascular disease. N Engl J Med 377:1319–1330CrossRefPubMed
57.
Dewilde WJ, Oirbans T, Verheugt FW et al (2013) Use of Clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomized, controlled trial. Lancet 381:1107–1115CrossRefPubMed
58.
Gibson CM, Mehran R, Bode C et al (2016) Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 375:2423–2434CrossRefPubMed
59.
Cannon CP, Bhatt DL, Oldgren J et al (2017) Dual antithrombotic therapy with Dabigatran after PCI in atrial fibrillation. N Eng J Med 377:1513–1524CrossRef
Metadaten
Titel
Management des akuten Koronarsyndroms
verfasst von
PD Dr. med. C. Liebetrau
A. Elsässer
H. Nef
H. Möllmann
Publikationsdatum
03.09.2018
Verlag
Springer Medizin
Erschienen in
Die Kardiologie / Ausgabe 5/2018
Print ISSN: 2731-7129
Elektronische ISSN: 2731-7137
DOI
https://doi.org/10.1007/s12181-018-0272-3

Weitere Artikel der Ausgabe 5/2018

Die Kardiologie 5/2018 Zur Ausgabe

Update Cardio

Konventionelle und interventionelle Klappentherapie

Journal Club

TAVI: Vor allem für „alte“ Patienten!

Curriculum

Manual zum Stellenwert der Ergometrie

Journal Club

Schlaganfall nach Koronarintervention signifikant seltener als nach Bypassoperation!

Positionspapier

Positionspapier Nuklearkardiologie – Update 2018

Praxiswissen EKG-Interpretation

47-Jähriger mit Dyspnoe und Schweißausbrüchen – was sehen Sie im EKG?